Works matching IS 22351795 AND DT 2022 AND VI 11
Results: 68
The 12th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2022).
- Published in:
- 2022
- Publication type:
- Abstract
Contents Vol. 11, 2022.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. I, doi. 10.1159/000528106
- Publication type:
- Article
Front & Back Matter.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 1, doi. 10.1159/000528495
- Publication type:
- Article
APPLE News.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 582, doi. 10.1159/000528105
- Publication type:
- Article
Acknowledgement to Reviewers.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 583, doi. 10.1159/000527592
- Publication type:
- Article
Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 487, doi. 10.1159/000527404
- By:
- Publication type:
- Article
Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 572, doi. 10.1159/000526388
- By:
- Publication type:
- Article
Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 511, doi. 10.1159/000526038
- By:
- Publication type:
- Article
Response to the Article on Antibiotics and Immune Checkpoint Inhibitors by Lin et al.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 578, doi. 10.1159/000526003
- By:
- Publication type:
- Article
Erratum.
- Published in:
- 2022
- Publication type:
- Correction Notice
Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 558, doi. 10.1159/000525671
- By:
- Publication type:
- Article
Hepatitis B Virus Treatment and Hepatocellular Carcinoma: Controversies and Approaches to Consensus.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 497, doi. 10.1159/000525518
- By:
- Publication type:
- Article
Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 540, doi. 10.1159/000525375
- By:
- Publication type:
- Article
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 527, doi. 10.1159/000525145
- By:
- Publication type:
- Article
Impact of Antibiotics Use on Cancer-Related and All-Cause Mortality among Patients Receiving Immunotherapy for Advanced Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 576, doi. 10.1159/000525028
- By:
- Publication type:
- Article
Front & Back Matter.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 5, p. 1, doi. 10.1159/000526882
- Publication type:
- Article
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 5, p. 399, doi. 10.1159/000526163
- By:
- Publication type:
- Article
Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 5, p. 426, doi. 10.1159/000525582
- By:
- Publication type:
- Article
Clinical Practice Guidelines for Hepatic Arterial Infusion Chemotherapy with a Port System Proposed by the Japanese Society of Interventional Radiology and Japanese Society of Implantable Port Assisted Treatment.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 5, p. 407, doi. 10.1159/000524893
- By:
- Publication type:
- Article
Front & Back Matter.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 4, p. 1, doi. 10.1159/000525876
- Publication type:
- Article
Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 5, p. 460, doi. 10.1159/000525488
- By:
- Publication type:
- Article
Exposure to Air Pollution and Survival in Follow-Up after Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 5, p. 474, doi. 10.1159/000525346
- By:
- Publication type:
- Article
Regarding "Postresection Period-Specific Hazard of Recurrence as a Framework for Surveillance Strategy in Patients with Hepatocellular Carcinoma: A Multicenter Outcome Study".
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 5, p. 483, doi. 10.1159/000525065
- By:
- Publication type:
- Article
Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 5, p. 440, doi. 10.1159/000525500
- By:
- Publication type:
- Article
Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres Followed by Gemcitabine plus Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 5, p. 451, doi. 10.1159/000525489
- By:
- Publication type:
- Article
APPLE News.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 4, p. 398, doi. 10.1159/000525668
- Publication type:
- Article
Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 4, p. 283, doi. 10.1159/000525467
- By:
- Publication type:
- Article
Erratum.
- Published in:
- 2022
- Publication type:
- Correction Notice
Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition).
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 4, p. 315, doi. 10.1159/000523997
- By:
- Publication type:
- Article
Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 4, p. 368, doi. 10.1159/000523849
- By:
- Publication type:
- Article
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 4, p. 354, doi. 10.1159/000522547
- By:
- Publication type:
- Article
Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 4, p. 383, doi. 10.1159/000522424
- By:
- Publication type:
- Article
Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 4, p. 290, doi. 10.1159/000522403
- By:
- Publication type:
- Article
Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 4, p. 329, doi. 10.1159/000522389
- By:
- Publication type:
- Article
Period-Dependent Survival Benefit of Percutaneous Microwave Ablation for Hepatocellular Carcinoma: A 12-Year Real-World, Multicentric Experience.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 4, p. 341, doi. 10.1159/000522134
- By:
- Publication type:
- Article
Front & Back Matter.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 3, p. 1, doi. 10.1159/000525471
- Publication type:
- Article
APPLE News.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 3, p. 281, doi. 10.1159/000525224
- Publication type:
- Article
Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 3, p. 185, doi. 10.1159/000524977
- By:
- Publication type:
- Article
First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 3, p. 268, doi. 10.1159/000522418
- By:
- Publication type:
- Article
A Hybrid Machine Learning Model Based on Semantic Information Can Optimize Treatment Decision for Naïve Single 3–5-cm HCC Patients.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 3, p. 256, doi. 10.1159/000522123
- By:
- Publication type:
- Article
Biomarkers for Locally Advanced Hepatocellular Carcinoma Patients Treated with Liver-Directed Combined Radiotherapy.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 3, p. 247, doi. 10.1159/000522000
- By:
- Publication type:
- Article
Subtype Classification of Intrahepatic Cholangiocarcinoma Using Liver MR Imaging Features and Its Prognostic Value.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 3, p. 233, doi. 10.1159/000521747
- By:
- Publication type:
- Article
Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 3, p. 219, doi. 10.1159/000521746
- By:
- Publication type:
- Article
Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trial).
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 3, p. 209, doi. 10.1159/000521665
- By:
- Publication type:
- Article
Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 3, p. 192, doi. 10.1159/000521596
- By:
- Publication type:
- Article
Regression of Tumor Thrombus in the Suprahepatic Vena Cava of Hepatocellular Carcinoma and Conversion Hepatectomy Induced by Lenvatinib.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 3, p. 278, doi. 10.1159/000520822
- By:
- Publication type:
- Article
Front & Back Matter.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 2, p. 1, doi. 10.1159/000524556
- Publication type:
- Article
APPLE News.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 2, p. 184, doi. 10.1159/000524373
- Publication type:
- Article
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 2, p. 87, doi. 10.1159/000523702
- By:
- Publication type:
- Article
Genetic Variant of CXCR1 (rs2234671) Associates with Clinical Outcome in Perihilar Cholangiocarcinoma.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 2, p. 162, doi. 10.1159/000521613
- By:
- Publication type:
- Article